EyePoint (EYPT) Stock Price
EyePoint Price
Revenue has compounded at 17.5% per year over the past 19 years to 31.37 M USD. EyePoint's net margin stands at -739.4%, down from -158.1% several years earlier.
EyePoint stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
EyePoint business model & stock analysis
Frequently asked questions about EyePoint
EyePoint Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The business model of EyePoint Pharmaceuticals Inc revolves around developing sustained-release drug delivery systems for the treatment of serious eye diseases. By utilizing its proprietary technologies, the company aims to improve patients' outcomes by providing long-lasting and targeted drug delivery options. EyePoint Pharmaceuticals Inc focuses on developing and commercializing products addressing unmet medical needs, ultimately enhancing the quality of life for individuals suffering from various eye conditions.
EyePoint Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of EyePoint Pharmaceuticals Inc in the market are Aerie Pharmaceuticals Inc and Ocular Therapeutix Inc.
EyePoint Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing and commercializing innovative ophthalmic products. Founded in 1987, EyePoint has a rich history of advancing patient care in the field of ophthalmology. With a strong focus on sustained-release drug delivery systems, the company has successfully developed and received regulatory approvals for several cutting-edge ophthalmic treatments. EyePoint Pharmaceuticals Inc continues to thrive as a leading player in the industry, catering to the needs of patients worldwide. With its commitment to innovation and improving eye health, EyePoint Pharmaceuticals Inc has become a trusted name in the pharmaceutical sector.
EyePoint Pharmaceuticals Inc has achieved several significant milestones in its history. The company has successfully developed and commercialized innovative ophthalmic treatments, making a positive impact on patient care. EyePoint Pharmaceuticals Inc received FDA approval for its sustained-release intraocular implant, DEXYCU®, which is used for treating inflammation after cataract surgery. Additionally, the company gained FDA approval for YUTIQ®, a micro-insert used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. These milestones demonstrate EyePoint Pharmaceuticals Inc's commitment to advancing therapeutic options in the field of ophthalmology.
EyePoint Pharmaceuticals Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered, as well as Europe, specifically Germany, France, and the United Kingdom. Additionally, EyePoint Pharmaceuticals Inc has a presence in selected markets in Asia, including Japan. With its global reach, EyePoint Pharmaceuticals Inc aims to bring innovative ophthalmic products and therapies to patients worldwide.
EyePoint Pharmaceuticals Inc represents a strong commitment to improving patient outcomes through advanced ophthalmic therapeutic solutions. With a focus on innovation, the company is dedicated to developing and commercializing sustained-release drug delivery technologies. EyePoint Pharmaceuticals strives to address unmet medical needs and provide convenient treatment options to patients suffering from serious eye conditions. By leveraging its expertise and cutting-edge research, EyePoint Pharmaceuticals aims to enhance the quality of life for individuals worldwide.
19 analysts currently rate the EyePoint stock: 13 recommend buying, 6 holding and 0 selling. For 2026, analysts expect EyePoint to generate revenue of 1.72 M USD and earnings per share of -2.52 USD.
Converted at the current exchange rate, the EyePoint share trades at 2.80 EUR (3.14 USD).
The EyePoint share (EYPT) is listed on 3 stock exchanges, including: NASDAQ (EYPT), Frankfurt (PV3B.F), München (PV3B.MU).
EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that develops and markets innovative drugs for body tissues and eye diseases. The company's business model focuses on the development, manufacturing, and marketing of therapeutics for chronic eye diseases such as macular degeneration, diabetic retinopathy, and uveitis. EyePoint Pharmaceuticals specializes in strategic partnerships and collaborations with renowned pharmaceutical companies and global organizations. The company offers drug solutions such as Iluvien, used for the treatment of macular degeneration, and Yutiq, intended for chronic uveitis therapy. Iluvien is a steroid implant composed of a unique formulation of fluocinolone acetonide (FAc) and a biopolymer that slowly degrades during use. It has a unique ability to exert a sustained effect on eye disease, significantly reducing the need for repeated intravitreal injections. Iluvien is approved in Europe and Canada and has been submitted to the US Food and Drug Administration (FDA). Yutiq is a steroid implant developed for the treatment of chronic uveitis. It is implanted into the posterior chamber of the eye and releases the active ingredient triamcinolone acetonide (TAc) to reduce inflammation. Yutiq has been approved by the FDA and is currently available in the United States. In addition, EyePoint Pharmaceuticals also offers Dexpel, a technology platform for long-lasting surgical implants. This platform can be utilized in various medical fields such as oncology, orthopedics, and neurosurgery to control drug release, prolong treatment duration, and reduce the need for repeated injections. EyePoint Pharmaceuticals also pursues a diversification strategy to expand its product portfolio and create stable growth. This includes collaborating with other companies to provide technology solutions and services tailored to the needs of customers. Overall, the business model of EyePoint Pharmaceuticals aims to bring innovative drugs to the market that enable effective treatment of eye diseases and significantly improve patients' quality of life. The company relies on a combination of well-established and innovative technologies to control drug release and ensure optimal therapy.
The expected revenue of EyePoint is 1.72 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of EyePoint is -209.36 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of EyePoint is currently -1.25. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the EyePoint stock.
The price-to-sales ratio (P/S) of EyePoint is currently 151.72. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the EyePoint stock.
The Eulerpool Quality Score for EyePoint is 2/10.
The ISIN of EyePoint is US30233G2093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of EyePoint is A2QJRU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of EyePoint is EYPT. The ticker symbol is used to trade EyePoint shares on the stock exchange.
EyePoint stock
EyePoint Peer Group
EyePoint Ticker
EyePoint FIGI
All fundamentals and in-depth analysis of EyePoint
Our stock analysis for EyePoint stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.